Dr. Loblaw on Monitoring Men With Intermediate-Risk Prostate Cancer

Andrew Loblaw, MD, FRCPC, MSc
Published: Friday, Feb 27, 2015



Andrew Loblaw, MD, FRCPC, MSc, clinician scientist, radiation oncologist, Sunnybrook Health Sciences Centre, discusses a study that looked at using active surveillance to monitor men with intermediate-risk prostate cancer.

This study analyzed approximately 950 men with low- or intermediate-risk disease. Patients were monitored using physical examinations, biopsies, and blood tests and were analyzed for the impact on overall survival, cost-specific survival, time to treatment, and PSA control.

In this study, the risk of dying from prostate cancer increased significantly when active surveillance was used in men with intermediate-risk disease compared with their low-risk counterparts.

Read more about this study > >

<<< View more from the 2015 GU Cancer Symposium



Andrew Loblaw, MD, FRCPC, MSc, clinician scientist, radiation oncologist, Sunnybrook Health Sciences Centre, discusses a study that looked at using active surveillance to monitor men with intermediate-risk prostate cancer.

This study analyzed approximately 950 men with low- or intermediate-risk disease. Patients were monitored using physical examinations, biopsies, and blood tests and were analyzed for the impact on overall survival, cost-specific survival, time to treatment, and PSA control.

In this study, the risk of dying from prostate cancer increased significantly when active surveillance was used in men with intermediate-risk disease compared with their low-risk counterparts.

Read more about this study > >

<<< View more from the 2015 GU Cancer Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x